THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2016

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2016

MARKETPLACE

New pathology lab products and industry news

Home » Top news

Promega seeks FDA approval for MSI assay

July 14, 2017Promega Corp. intends to seek FDA approval of and CE-IVD marking for a commercially available microsatellite instability assay to assist oncologists and pathologists in determining colorectal cancer decisions. MSI status is a measure of mismatch-repair deficiency commonly found in solid tumors. In addition to the colorectal cancer intended use, Promega intends to investigate additional possible applications for the MSI diagnostic test.

More top news

Print Friendly
Tags:

X